Drug Topics
JULY 19, 2024
Steve Postal, JD, Director of Policy and Regulatory Affairs at the National Community Pharmacists Association (NCPA), discussed pharmacy benefit managers and vehicles necessary to induce reform.
STAT
JULY 19, 2024
On Thursday, a widespread outage to Microsoft systems took down computers in health systems around the globe, leading many to cancel non-urgent medical appointments and surgeries as they encouraged patients to make plans for disrupted travel and delays in care. “A major worldwide software outage has affected many of our systems at Mass General Brigham,” the hospital system shared in a statement on Friday.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JULY 19, 2024
The collaboration between Surescripts and DAW Systems leverages Surescripts’ established e-prescribing network, which last year processed 2.5 billion prescriptions from 1.29 million prescribers across the US.
STAT
JULY 19, 2024
WastewaterSCAN, one of the United States’ largest private entities that provide real-time data on pathogens in wastewater, has stopped collecting data from 43 facilities due to “resource constraints,” according to emails the company sent to staff overseeing these sites. The group — based at Stanford University, in partnership with Emory University — had been collecting samples from 194 sites in 41 states and the District of Columbia, a swath including 39 millio
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Healthcare
JULY 19, 2024
A widespread outage to Microsoft systems has impacted health systems, hospitals and clinics as electronic health record software has been knocked offline, forcing providers to cancel non-emergency | A widespread outage to Microsoft systems has impacted health systems, hospitals and clinics as electronic health record software has been knocked offline, forcing providers to cancel non-emergency procedures and services.
STAT
JULY 19, 2024
The first time I saw Maya (not her real name) huddled under blankets in a hospital bed in 2013, she had been to dozens of inpatient detox programs and residential treatment centers since she had begun using heroin two decades earlier. After every release, she returned to heroin use, usually within days. Why didn’t treatment “stick”?
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
JULY 19, 2024
In an era of rapid scientific and technological advances when politicians and scientists are struggling to find the right balance between innovation and safety, Sen. Rand Paul (R-Ky.) has introduced the Risky Research Review Act (S. 4667) in an effort to navigate this treacherous terrain. But instead of providing clarity and security, this legislation threatens to cast a shadow over the future of life sciences research and slow it down.
Pharmacy Times
JULY 19, 2024
Individuals that followed the Mediterranean diet with EPA-DHA supplements displayed an increase in omega-3 levels which improved clinical appearance.
STAT
JULY 19, 2024
At a contentious advisory committee meeting in June, the Food and Drug Administration announced it was investigating allegations of data suppression and misconduct in clinical trials of MDMA-assisted therapy. The agency was “quite concerned” by claims included in a report from the Institute for Clinical and Economic Review think tank, agency psychiatry director Tiffany Farchione told the ad comm, and planned to complete its investigation before deciding whether to approve Lykos The
Fierce Healthcare
JULY 19, 2024
Kidney care giant DaVita has agreed to pay nearly $34.5 million to settle allegations that it paid kickbacks to secure referrals, according to an announcement from the Justice Department. | Kidney care giant DaVita has agreed to pay nearly $34.5 million to settle allegations that it paid kickbacks to secure referrals, according to an announcement from the Justice Department.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
JULY 19, 2024
Delgocitinib cream from LEO Pharmaceuticals showed superior efficacy compared to cream vehicle and was well tolerated over 16 weeks.
Fierce Healthcare
JULY 19, 2024
Infectious disease professionals are calling for greater federal funding in the face of new Centers for Disease Contral and Prevention (CDC) data outlining an uptick in antimicrobial-resistant path | Seven antimicrobial-resistant, hospital-onset infection rates remained 20% higher in 2022 from prepandemic levels.
STAT
JULY 19, 2024
By dismissing a case that would have determined whether emergency abortion care is encompassed under the Emergency Medical Treatment and Labor Act (EMTALA), along with other protected emergency care services, the Supreme Court of the United States has opened the door for states to deny women stabilizing and often lifesaving medical procedures. For nearly 40 years, EMTALA has protected access to emergency services regardless of a person’s ability to pay, citizenship, or legal status.
pharmaphorum
JULY 19, 2024
Explore the emerging uses and future directions of chimeric antigen receptor T-cell therapy targeting mRNA, anti-EGFRvIII, and anti-NY-ESO-1 antigens in cancer treatments.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
JULY 19, 2024
There were positive efficacy and safety results for tivozanib monotherapy consistent with previous analyses.
pharmaphorum
JULY 19, 2024
Explore the emerging era of digital health and pharmaceuticals with PDURS, featuring insights from industry experts Marty Culjat of EVERSANA and Edward Cox of Pfizer.
Pharmafile
JULY 19, 2024
GSK has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for Blenrep (belantamab mafodotin) in combination with bortezombin plus dexamethasone (BorDex) or pomalidomide plus dexamethasone (PomDex) as a treatment for relapsed or refractory (R/R) multiple myeloma (MM). The post GSK’s application for Blenrep for MM treatment accepted for EMA review appeared first on Pharmafile.
pharmaphorum
JULY 19, 2024
FDA will create a rare disease hub to speed the development of new treatments and build connections between developers and the rare disease community
Pharmaceutical Commerce
JULY 19, 2024
FDA to review one-year results for Susvimo showing non-inferior visual acuity gains in diabetic macular edema and in the Diabetic Retinopathy Severity Scale for Diabetic Retinopathy.
pharmaphorum
JULY 19, 2024
While the pace of biotech private rounds seems to have slowed a little of late, this week saw four big financings for Cardurion Pharma, Scorpion Therapeutics, CatalYm, and NGM Bio.Burlington, Massachusetts-based Cardurion led the quartet with a $260 million Series B for its heart-focused drug pipeline, which features two candidates in phase 2 testing – PDE9 inhibitor CRD-750 for heart failure and CaMKII inhibitor CRD-4730 for rare genetic disease catecholaminergic polymorphic ventricular tachyca
Pharmacy Times
JULY 19, 2024
More cost effectiveness data is crucial in advocating for better insurance coverage in the United States.
pharmaphorum
JULY 19, 2024
Less than two years after pulling multiple myeloma therapy Blenrep off most markets around the world, GSK has filed for approval of the drug in the EU once again, hoping to restore its blockbuster credentials.The remarkable renaissance for the BCMA-directed antibody-drug conjugate is supported by a pair of phase 3 trials that could not only support its return but also make it an option for a much larger patient population than before.
Outsourcing Pharma
JULY 19, 2024
Avista, a New York-based private equity firm focused on healthcare, and Hamilton Lane, a global private markets investment management firm, have announced that funds managed by Hamilton Lane have acquired a significant equity interest in Cosette Pharmaceuticals from Avista and its co-investors.
Fierce Healthcare
JULY 19, 2024
Healthcare technology company Commure plans to buy Augmedix, a healthcare artificial intelligence company founded in 2013, the companies announced Friday. | On Friday, ambient AI documentation company Augmedix announced it had been bought by Commure, a large IT vendor to healthcare systems. The deal values the company at $139 million.
Pharmacy Times
JULY 19, 2024
The importance of protecting the skin is often underestimated by patients
Fierce Pharma
JULY 19, 2024
While the national IT outrage caused by cybersecurity specialist CrowdStrike—and subsequently Microsoft—has grounded airlines and forced cancelations at hospitals, the experience from the meltdown | While the national IT outrage caused by cybersecurity specialist CrowdStrike—and subsequently Microsoft—has grounded airlines and forced cancelations at hospitals, the experience from the meltdown appeared different among large pharma companies.
Outsourcing Pharma
JULY 19, 2024
Phathom Pharmaceuticals, Inc.dedicated to developing and commercializing treatments for gastrointestinal (GI) diseases, announced today that the US Food and Drug Administration (FDA) has approved Voquenza (vonoprazan) 10mg tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (non-erosive GERD) in adults.
STAT
JULY 19, 2024
For many New Yorkers, Dave Chokshi was the face of New York City’s public health response to Covid-19. He often appeared on public service announcements in a white lab coat emblazoned with“N-Y-C” in big, bold letters, urging urbanites to mask up , get tested , and get vaccinated. Appointed as New York City’s 43rd health commissioner in August 2020, Chokshi was thrust into the city’s battle against the coronavirus just months after it was deemed an epicenter of
pharmaphorum
JULY 19, 2024
NICE backs NHS use of Accord's Orgovyx, the first therapy for advanced hormone-sensitive prostate cancer that can be taken at home
STAT
JULY 19, 2024
Hellloooooo. Today, we discuss the FDA’s lack of engagement with critics of MDMA for PTSD therapy. We also highlight a massive veterans study on genomics, and how it illustrates the importance of studying diverse populations. And there’s more. FDA silent on claims of misconduct in MDMA trials At last month’s advisory committee meeting about Lykos Therapeutics’ MDMA-assisted therapy, the FDA said that it would investigate allegations of data suppression and misconduct
Pharmacy Times
JULY 19, 2024
Confusing product labeling and conflicting data can create challenges for patients.
STAT
JULY 19, 2024
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, so far, includes fraternizing with assorted family types, promenading with the official mascots, and catching up on our reading. We also hope to hold another listening party, where the rotation will likely include this , this , this and this.
Fierce Pharma
JULY 19, 2024
A 10-page Form 483 has detailed the shortfalls at Hengrui Pharma's PD-1 plant behind a recent FDA rejection. Sanofi is investing heavily to expand its global capacity center in India. | A 10-observation Form 483 has detailed the shortfalls at Hengrui Pharma's PD-1 plant behind its recent FDA rejection. Sanofi is investing heavily to expand its global capacity center in India.
Pharmacy Times
JULY 19, 2024
The findings showed that pharmacist-led interventions resulted in the greatest systolic blood pressure reductions.
Expert insights. Personalized for you.
200 
Let's personalize your content